{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:55:41Z","timestamp":1789206941783,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1136\/ard.2006.055269","type":"journal-article","created":{"date-parts":[[2006,5,17]],"date-time":"2006-05-17T20:34:04Z","timestamp":1147898044000},"page":"1312-1324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":940,"title":["EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)"],"prefix":"10.1016","volume":"65","author":[{"given":"W","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Barskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Gerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Netter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Nuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pignone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Piment\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Punzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Roddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Zimmermann-G\u00f2rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2006.055269_bib1","first-page":"104","article-title":"Frequency of inappropriate management of acute gout attacks","volume":"33","author":"Neogi","year":"2006","journal-title":"J Rheumatol"},{"issue":"9 suppl","key":"10.1136\/ard.2006.055269_bib2","first-page":"S339","article-title":"Medication errors with the use of gout related therapies: results from the United States Pharmacopeia MEDMARXsm Surveillance System","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: Diagnosis","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1136\/ard.2004.028886","article-title":"EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"64","author":"Zhang","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib5","series-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"10.1136\/ard.2006.055269_bib6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","article-title":"The number needed to treat: a clinically useful measure of treatment effect","volume":"310","author":"Cook","year":"1995","journal-title":"BMJ"},{"key":"10.1136\/ard.2006.055269_bib7","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard.2006.055269_bib8","series-title":"Epidemiologic research \u2013 principles and quantitative methods","author":"Kleinbaum","year":"1982"},{"key":"10.1136\/ard.2006.055269_bib9","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/sim.4780101105","article-title":"A general parametric approach to the meta-analysis of randomized clinical trials","volume":"10","author":"Whitehead","year":"1991","journal-title":"Stat Med"},{"key":"10.1136\/ard.2006.055269_bib10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2006.055269_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/art.1780080456","article-title":"The effect of allopurinol in primary and secondary gout","volume":"8","author":"Yu","year":"1965","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/978-1-4757-1433-3_28","article-title":"Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects","volume":"41","author":"Rosenfeld","year":"1974","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/ard.59.7.539","article-title":"Beneficial effects of weight loss associated with moderate calorie\/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study","volume":"59","author":"Dessein","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib16","first-page":"134","article-title":"Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure [in German]","volume":"28","author":"Kullich","year":"1989","journal-title":"Rehabilitation"},{"key":"10.1136\/ard.2006.055269_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust NZ J Med"},{"key":"10.1136\/ard.2006.055269_bib18","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib19","first-page":"494","article-title":"Acute colchicine intoxication \u2013 possible role of erythromycin administration","volume":"19","author":"Caraco","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib20","first-page":"421","article-title":"Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine","volume":"16","author":"Minetti","year":"2003","journal-title":"J Nephrol"},{"key":"10.1136\/ard.2006.055269_bib21","first-page":"92","article-title":"A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis [in Spanish]","volume":"14","author":"Garcia de la Torre","year":"1987","journal-title":"Investigacion Medica Internacional"},{"key":"10.1136\/ard.2006.055269_bib22","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1742-1241.1982.tb08433.x","article-title":"Azapropazone or allopurinol in the treatment of chronic gout and\/or hyperuricaemia. A preliminary report","volume":"36","author":"Templeton","year":"1982","journal-title":"Br J Clin Pract"},{"key":"10.1136\/ard.2006.055269_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-1-4615-9140-5_42","article-title":"A controlled study of the effect of long term allopurinol treatment on renal function in gout","volume":"122A","author":"Gibson","year":"1980","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0026-0495(88)90098-4","article-title":"Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial","volume":"37","author":"Bastow","year":"1988","journal-title":"Metab Clin Exp"},{"key":"10.1136\/ard.2006.055269_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard.2006.055269_bib28","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, daily and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.055269_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-4757-1433-3_16","article-title":"Observations concerning the incidence of disturbance of lipid and carbohydrate metabolism in gout","volume":"41","author":"Frank","year":"1974","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib30","first-page":"774","article-title":"Cholesterol distribution among lipoprotein fractions in patients with gout and normal controls","volume":"13","author":"Jacobelli","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ard.54.2.90","article-title":"Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout","volume":"54","author":"Takahashi","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib32","first-page":"1152","article-title":"Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia","volume":"31","author":"Lin","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/978-1-4757-1433-3_10","article-title":"Relationship between gout and arterial hypertension","volume":"41","author":"Rapado","year":"1974","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/sj.jhh.1000496","article-title":"Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up","volume":"11","author":"Grodzicki","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1136\/ard.2006.055269_bib35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/oxfordjournals.aje.a114807","article-title":"Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji","volume":"127","author":"Tuomilehto","year":"1988","journal-title":"Am J Epidemiol"},{"key":"10.1136\/ard.2006.055269_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/ajcn\/78.4.690","article-title":"A case-control study of the association of diet and obesity with gout in Taiwan","volume":"78","author":"Lyu","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1136\/ard.2006.055269_bib37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/j.1360-0443.2003.00553.x","article-title":"The alcohol-tobacco relationship: a prospective study among adolescents in six European countries","volume":"98","author":"Wetzels","year":"2003","journal-title":"Addiction"},{"key":"10.1136\/ard.2006.055269_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2006.055269_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00004872-200202000-00027","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout","volume":"20","author":"Liberopoulos","year":"2002","journal-title":"J Hypertens"},{"key":"10.1136\/ard.2006.055269_bib40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/00004872-199917070-00021","article-title":"Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension","volume":"17","author":"Puig","year":"1999","journal-title":"J Hypertens"},{"key":"10.1136\/ard.2006.055269_bib41","first-page":"M37","article-title":"Effect of a combination therapy with losartan and anti-hyperuricemic agents on uric acid metabolism in gout patients with hypertension","volume":"28","author":"Takahashi","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib43","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","article-title":"Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout","volume":"19","author":"Wurzner","year":"2001","journal-title":"J Hypertens"},{"key":"10.1136\/ard.2006.055269_bib44","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relation between adverse events associated with allopurinol and renal function in patients with gout","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib45","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/archopht.116.12.1652","article-title":"Exposure to allopurinol and the risk of cataract extraction in elderly patients","volume":"116","author":"Garbe","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1136\/ard.2006.055269_bib46","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0736-4679(02)00430-4","article-title":"Deaths associated with inappropriate intravenous colchicine administration","volume":"22","author":"Bonnel","year":"2002","journal-title":"J Emerg Med"},{"key":"10.1136\/ard.2006.055269_bib47","first-page":"143","article-title":"A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed","volume":"23","author":"Evans","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib48","first-page":"1422","article-title":"Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study","volume":"15","author":"Altman","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib49","first-page":"157","article-title":"A comparison of azapropazone and allopurinol in the treatment of chronic gout","volume":"15","author":"Daymond","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.2006.055269_bib50","first-page":"275","article-title":"A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout","volume":"10","author":"Douglas","year":"1970","journal-title":"Ann Phys Med"},{"key":"10.1136\/ard.2006.055269_bib51","first-page":"641","article-title":"Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study","volume":"33","author":"Eberl","year":"1983","journal-title":"Arzneimittel-Forschung"},{"key":"10.1136\/ard.2006.055269_bib52","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia","volume":"37","author":"Fraser","year":"1987","journal-title":"J R Coll Gen Pract"},{"key":"10.1136\/ard.2006.055269_bib53","first-page":"540","article-title":"The treatment of acute gout arthritis. Double-blind randomized comparative study between nimesulid and indomethacin","volume":"53","author":"Klumb","year":"1996","journal-title":"Rev Brasil Med"},{"key":"10.1136\/ard.2006.055269_bib54","first-page":"344","article-title":"A double-blind comparison of Etodolac (Lodine (R)) and high doses of naproxen in the treatment of acute gout","volume":"7","author":"Lederman","year":"1990","journal-title":"Adv Ther"},{"key":"10.1136\/ard.2006.055269_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9343(86)90131-2","article-title":"Flurbiprofen in the treatment of acute gout. A comparison with indomethacin","volume":"80","author":"Lomen","year":"1986","journal-title":"Am J Med"},{"key":"10.1136\/ard.2006.055269_bib56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac (\u2018Lodine\u2019) compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1136\/ard.2006.055269_bib57","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1185\/03007998009109465","article-title":"Double-blind trial of feprazone and phenylbutazone in acute gout","volume":"6","author":"Reardon","year":"1980","journal-title":"Curr Med Res Opin"},{"key":"10.1136\/ard.2006.055269_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/03009747809095668","article-title":"Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial","volume":"21","author":"Ruotsi","year":"1978","journal-title":"Scand J Rheumatol Suppl"},{"key":"10.1136\/ard.2006.055269_bib59","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0196-0644(95)70037-4","article-title":"Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis","volume":"26","author":"Shrestha","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1136\/ard.2006.055269_bib60","first-page":"535","article-title":"Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author\u00e2\u20ac\u2122s translation) [in German]","volume":"88","author":"Siegmeth","year":"1976","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1136\/ard.2006.055269_bib61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/978-1-4684-3285-5_44","article-title":"Multi-centre trial of naproxen and phenylbutazone in acute gout","volume":"76B","author":"Sturge","year":"1977","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib62","first-page":"111","article-title":"Piroxicam in treatment of acute gout high dose versus low dose","volume":"68","author":"Tumrasvin","year":"1985","journal-title":"J Med Assoc Thailand"},{"key":"10.1136\/ard.2006.055269_bib63","first-page":"915","article-title":"An evaluation of piroxicam, a new non-steroidal anti-inflammatory agent. A multicentre trial","volume":"59","author":"Tweddell","year":"1981","journal-title":"S Afr Med J"},{"key":"10.1136\/ard.2006.055269_bib64","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/art.1780220420","article-title":"Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis","volume":"22","author":"Weiner","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0149-2918(04)90035-5","article-title":"A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1136\/ard.2006.055269_bib66","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib67","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1136\/ard.2006.055269_bib68","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.055269_bib69","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2006.055269_bib70","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/bmj.327.7426.1275","article-title":"Lesson of the week \u2013 colchicine in acute gout","volume":"327","author":"Morris","year":"2003","journal-title":"BMJ"},{"key":"10.1136\/ard.2006.055269_bib71","first-page":"2285","article-title":"Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide","volume":"26","author":"Fernandez","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib72","first-page":"111","article-title":"Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis","volume":"20","author":"Alloway","year":"1920","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0049-0172(90)90070-V","article-title":"Systemic steroid therapy for acute gout: a clinical trial and review of the literature [review] [40 refs]","volume":"19","author":"Groff","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib74","first-page":"1325","article-title":"Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis","volume":"21","author":"Siegel","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1345\/aph.10230","article-title":"Corticotropin for acute management of gout","volume":"35","author":"Taylor","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2006.055269_bib76","first-page":"248","article-title":"Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs [see comment]","volume":"63","author":"Werlen","year":"1996","journal-title":"Rev Rhum (English edition)"},{"key":"10.1136\/ard.2006.055269_bib77","first-page":"355","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib78","first-page":"577","article-title":"Treatment of chronic gout. can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1136\/ard.2006.055269_bib80","first-page":"908","article-title":"A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis","volume":"22","author":"Ferraz","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib81","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1136\/ard.2006.055269_bib82","first-page":"60","article-title":"A safety and efficacy clinical trial of a novel nun-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout","volume":"63","author":"Becker","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib83","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib84","first-page":"S142","article-title":"Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout","volume":"46","author":"Joseph-Ridge","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib85","first-page":"S530","article-title":"Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase\/xanthine dehydrogenase inhibitor, for gout and hyperuricemia","volume":"48","author":"Kamatani","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib86","first-page":"S336","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia","volume":"50","author":"Kamatani","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib87","first-page":"S337","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia","volume":"50","author":"Kamatani","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib88","first-page":"498","article-title":"Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients \u2013 therapeutic equivalence to allopurinol","volume":"23","author":"WalterSack","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib89","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-85-3-333","article-title":"Allergic reaction to allopurinol with cross-reactivity to oxypurinol","volume":"85","author":"Lockard","year":"1976","journal-title":"Ann Intern Med"},{"issue":"suppl 9","key":"10.1136\/ard.2006.055269_bib90","first-page":"S159","article-title":"Oxypurinol therapy in allopurinol-sensitive patients [abstract]","volume":"36","author":"O\u00e2\u20ac\u2122Duffy","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib91","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0002-9343(92)90236-5","article-title":"Desensitization to allopurinol in patients with gout and cutaneous reactions","volume":"93","author":"Fam","year":"1992","journal-title":"Am J Med"},{"key":"10.1136\/ard.2006.055269_bib92","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7","article-title":"Efficacy and safety of desensitization to allopurinol following cutaneous reactions","volume":"44","author":"Fam","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib93","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3949\/ccjm.68.7.597","article-title":"How should hyperuricemia be treated in a patient with allopurinol hypersensitivity?","volume":"68","author":"Monev","year":"2001","journal-title":"Cleveland Clin J Med"},{"key":"10.1136\/ard.2006.055269_bib94","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.1780341020","article-title":"Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization","volume":"34","author":"Walz-LeBlanc","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib95","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/ard.25.Suppl_6.623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/1529-0131(195906)2:3<193::AID-ART1780020302>3.0.CO;2-8","article-title":"Gout: six-year follow-up on probenecid (benemid) therapy","volume":"2","author":"Bartels","year":"1959","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2006.055269_bib97","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \u2018absence of evidence is evidence of absence\u2019?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2006.055269_bib98","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2957\/kanzo.45.354","article-title":"A case of subacute hepatic failure associated with benzbromarone [in Japanese]","volume":"24","author":"Marukawa","year":"2004","journal-title":"Acta Hepatol Jpn"},{"key":"10.1136\/ard.2006.055269_bib99","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1046\/j.1440-1746.2002.02692.x","article-title":"Fulminant hepatic failure associated with benzbromarone treatment: a case report","volume":"17","author":"Arai","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1136\/ard.2006.055269_bib100","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0168-8278(00)80263-9","article-title":"Fatal fulminant hepatic failure associated with benzbromarone","volume":"32","author":"Wagayama","year":"2000","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2006.055269_bib101","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(94)80011-1","article-title":"Hepatic injury caused by benzbromarone","volume":"20","author":"Van Der Klauw","year":"1994","journal-title":"J Hepatol"},{"key":"10.1136\/ard.2006.055269_bib102","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1136\/ard.2006.055269_bib103","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","article-title":"Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999","volume":"64","author":"Mikuls","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib104","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2003.011742","article-title":"EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)","volume":"62","author":"Jordan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/ard.59.12.936","article-title":"EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)","volume":"59","author":"Pendleton","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib106","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2006.055269_bib107","unstructured":"Prodigy Guidance \u2013 Gout. http:\/\/www.prodigynhs.co.uk\/guideline\/asp?gt=Gout 2004; accessed 09-05-2005."},{"key":"10.1136\/ard.2006.055269_bib108","first-page":"961","article-title":"Hyperuricaemia and gout: clinical guidelines","volume":"93","author":"Meyers","year":"2003","journal-title":"S Afr Med J"},{"issue":"suppl 1","key":"10.1136\/ard.2006.055269_bib109","first-page":"442","article-title":"Introduction of the new guideline for the management of hyperuricemia and gout with special reference to its policy","volume":"61","author":"Nakajima","year":"2003","journal-title":"Jpn J Clin Med"},{"key":"10.1136\/ard.2006.055269_bib110","first-page":"309","article-title":"Dutch general practitioners gout guidelines","volume":"146","author":"Roemjinders","year":"2002","journal-title":"Ned Tijd Genees"},{"key":"10.1136\/ard.2006.055269_bib111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.318.7183.593","article-title":"Clinical guidelines: developing guidelines [review]","volume":"318","author":"Shekelle","year":"1999","journal-title":"BMJ"},{"key":"10.1136\/ard.2006.055269_bib112","first-page":"1193","article-title":"The periodic health examination","volume":"121","year":"1979","journal-title":"Can Med Assoc J"},{"key":"10.1136\/ard.2006.055269_bib113","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/rheumatology\/keh399","article-title":"Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee \u2013 the MOVE consensus","volume":"44","author":"Roddy","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2006.055269_bib114","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2006.055269_bib115","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1136\/ard.2006.055269_bib116","first-page":"196","article-title":"Transferring evidence from research into practice. 1. The role of clinical care research evidence in clinical decisions","volume":"1","author":"Hynes","year":"1996","journal-title":"Evidence Based Medicine"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724200224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2006.055269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T09:26:40Z","timestamp":1736069200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724200224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0003496724200224"],"URL":"https:\/\/doi.org\/10.1136\/ard.2006.055269","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.055269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1136\/ard.2006.055251","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Copyright 2006 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}